secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001193125-22-257259
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness
--------------------------------------------------------------------------------

- BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.
- Phase 2 trial of VIR-2482 expected to start H2 2022; initial data anticipated mid-2023.
- Potential total investment up to $1B if BARDA exercises up to 12 options for additional candidates.
- Contract supports development of up to 10 emerging infectious disease or medical countermeasure candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/0001193125-22-257259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312522257259/d387221d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-257259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer